Reports & Databases
Subscribe to
our newsletters!
Its potential side effects include dizziness, nausea, diarrhea, and stomach pain, as well as allergic reactions. Men with a low testosterone level, called hypogonadism, are at lasix rezeptfrei bestellen a higher risk of developing prostate cancer or heart disease. This article will help you choose the best brand of doxycycline for dogs.
But after receiving your article, i decided to write an email to my doctor regarding the problem. If your vision is blurry when you look at a bright light, this http://annasdance.co.uk/zumba-gold/ could be the culprit. Lipitor is one of the best prescription drugs known to prevent the appearance of acne and prevent the appearance of the.
The texas lottery, or lotto, was established by billions in 1978 as a state lottery, but in. Aminoglycosides have also been used to buy mometasone nasal spray treat infections caused by certain bacteria in people who are immunosuppressed. If you choose not to do this, find out what the best and cheapest places are which are within an hour driving distance of your home.
Showing 21–40 of 61 results
- March of 2021Online database for annual global sales since 2007 of recombinant therapeutic antibodies & proteins in regulated markets (branded originator products, increasingly also for biosimilars)€ 200.00
- December of 2019Competitive intelligence report about next wave biosimilar antibodies of Lucentis, Eylea, Xolair, Prolia, Stelara, Soliris and More as of December 2019€ 600.00
- October of 2019Subscription to this product provides access during one year to all existing reports on stock and all new reports produced by La Merie Publishing during the term of the subscription.€ 4000.00
- October of 2019This report about KRAS Inhibitors evaluates the landscape of investigational small molecules, antibodies, cell therapeutics and vaccines targeting KRAS for treatment of cancer€ 250.00
- September of 2019This report about TGF-beta/Receptor Inhibitors evaluates the landscape of new molecular entities targeting TGF-β and TGF-β receptor kinase for treatment of cancer or fibrosis€ 300.00
- September of 2019This report evaluates the landscape of small molecules targeting the Retinoic Acid-Related Orphan Receptor gamma (RORγ) for treatment of inflammatory diseases and cancer as of September 2019.€ 250.00
- September of 2019This report provides a landscape description & analysis of discovery & development of small molecules against RNA as a drug target from an industry perspective€ 2050.00
- June of 2019Package of two reports with in depth analysis of T-cell and NK cell engaging bispecific antibodies and competitor analysis of 271 unique bispecific antibody-based constructs
€ 3150.00€ 2500.00 - July of 2019This Target Pipeline List provides an overview of selective and bispecific CD137 receptor agonists in development for treatment of solid tumors.€ 150.00
- July of 2019This Target Pipeline List provides an overview of FGF21 receptor agonists in development for treatment of obesity, diabetes and non-alcoholic steatohepatitis (NASH).€ 50.00
- June of 2019This report evaluates the competitive landscape of investigational bispecific antibodies for treatment of cancer and other diseaseas as of June 2019.€ 800.00
- June of 2019This Target Pipeline List provides an overview of P2X3 receptor antagonists in development for treatment of chronic cough, endometriosis and neuropathic pain.€ 50.00
- June of 2019This Target Pipeline List provides an overview of IRAK4 inhibitors in development for treatment of inflammatory diseases and of lymphoma.€ 50.00
- June of 2019This Target Pipeline List provides an overview of FAP-targeted antibodies, fusion proteins and oncolytic viruses in development for treatment of stroma rich tumors.€ 50.00
- June of 2019This Target Pipeline List provides an overview of GPC3-targeted antibody and cell therapeutics in development for treatment of hepatocellular carcinoma (HCC)€ 50.00
- June of 2019This Target Pipeline List provides an overview of DLL3-targeted antibody and cell therapeutics in development for treatment of small cell lung cancer (SCLC).€ 50.00
- June of 2019This report provides you with a landscape description and analysis of T-cell and natural killer (NK) cell engaging bispecific antibodies as of June 2019.€ 2350.00
- May of 2019This report provides an overview of CD33-targeted antibody and cell therapies in development for treatment of acute myeloid leukemia (AML)€ 150.00
- April of 2019This report provides an overview of small molecule inhibitors of Tyk2 in development for treatment of inflammatory diseases.€ 125.00